{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:32:39Z","timestamp":1784827959115,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.trim.2024.102165","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T16:21:58Z","timestamp":1734798118000},"page":"102165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Novel insights into the circ_0003489\/let-7b-5p\/GLUT1 axis and its possible role in multiple myeloma"],"prefix":"10.1016","volume":"88","author":[{"given":"Xiaoyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuedi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 annual meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.trim.2024.102165_bb0010","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood.2020006045","article-title":"Monoclonal immunoglobulins promote bone loss in multiple myeloma","volume":"136","author":"Westhrin","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.trim.2024.102165_bb0015","article-title":"Bleeding diathesis in multiple myeloma: a rare presentation of a dreadful emergency with management nightmare","volume":"13","author":"Rahman","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.trim.2024.102165_bb0020","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5005\/jp-journals-10024-3108","article-title":"Oral conditions of elders and middle-aged individuals with multiple myeloma","volume":"22","author":"Bezerra","year":"2021","journal-title":"J. Contemp. Dent. Pract."},{"issue":"3","key":"10.1016\/j.trim.2024.102165_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.trim.2024.102165_bb0030","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.trim.2024.102165_bb0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molcel.2014.08.019","article-title":"circRNA biogenesis competes with pre-mRNA splicing","volume":"56","author":"Ashwal-Fluss","year":"2014","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-018-0827-8","article-title":"Circular RNAs function as ceRNAs to regulate and control human cancer progression","volume":"17","author":"Zhong","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trim.2024.102165_bb0050","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2147\/OTT.S297140","article-title":"Tip of the iceberg: roles of CircRNAs in Cancer glycolysis","volume":"14","author":"Li","year":"2021","journal-title":"Onco. Targets Ther."},{"issue":"3","key":"10.1016\/j.trim.2024.102165_bb0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jb\/mvaa106","article-title":"Upregulation of circ_0000142 promotes multiple myeloma progression by adsorbing miR-610 and upregulating AKT3 expression","volume":"169","author":"Liu","year":"2021","journal-title":"J. Biochem."},{"key":"10.1016\/j.trim.2024.102165_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118506","article-title":"CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p\/PRKCD axis in multiple myeloma","volume":"262","author":"Liu","year":"2020","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.trim.2024.102165_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3329","article-title":"Inhibition of hsa_circ_0003489 shifts balance from autophagy to apoptosis and sensitizes multiple myeloma cells to bortezomib via miR-874-3p\/HDAC1 axis","volume":"23","author":"Tian","year":"2021","journal-title":"J. Gene Med."},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0070","first-page":"951","article-title":"Circ_0003489 facilitates multiple myeloma progression by targeting miR-433-3p\/PBX3 axis","volume":"27","author":"Yan","year":"2022","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.trim.2024.102165_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.trim.2024.102165_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106565","article-title":"Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p\/PIM1 axis","volume":"106","author":"Wu","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.trim.2024.102165_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155495","article-title":"Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt\/beta-catenin\/Versican signaling pathway","volume":"142","author":"Chen","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12967-019-1882-7","article-title":"Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma","volume":"17","author":"Xi","year":"2019","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.trim.2024.102165_bb0095","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/CAD.0000000000000942","article-title":"Long non-coding RNA X-inactive-specific transcript contributes to cisplatin resistance in gastric cancer by sponging miR-let-7b","volume":"31","author":"Han","year":"2020","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0100","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1080\/21655979.2021.1982276","article-title":"Silencing of let-7b-5p inhibits ovarian cancer cell proliferation and stemness characteristics by asp-Glu-ala-asp-box helicase 19A","volume":"12","author":"Huang","year":"2021","journal-title":"Bioengineered"},{"issue":"11","key":"10.1016\/j.trim.2024.102165_bb0105","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/abbs\/gmu089","article-title":"Let-7b-5p regulates proliferation and apoptosis in multiple myeloma by targeting IGF1R","volume":"46","author":"Xu","year":"2014","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"3","key":"10.1016\/j.trim.2024.102165_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.trim.2024.102165_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2015.12.008","article-title":"Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents","volume":"41","author":"Matsumoto","year":"2016","journal-title":"Leuk. Res."},{"issue":"23","key":"10.1016\/j.trim.2024.102165_bb0120","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1080\/15384101.2020.1839701","article-title":"Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p\/JAG1 axis","volume":"19","author":"Wang","year":"2020","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.trim.2024.102165_bb0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/15384047.2018.1529091","article-title":"LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1\/miR-451\/TRIM66 axis","volume":"20","author":"Wang","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of Cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.trim.2024.102165_bb0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trim.2024.102165_bb0140","article-title":"CircRNA circ_0006677 inhibits the progression and glycolysis in non-small-cell lung Cancer by sponging miR-578 and regulating SOCS2 expression","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trim.2024.102165_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbrc.2021.04.131","article-title":"Knockdown of circBFAR inhibits proliferation and glycolysis in gastric cancer by sponging miR-513a-3p\/hexokinase 2 axis","volume":"560","author":"Wang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.trim.2024.102165_bb0150","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jmoldx.2015.06.006","article-title":"Aberrant levels of miRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression","volume":"17","author":"Wang","year":"2015","journal-title":"J. Mol. Diagnost.: JMD"},{"issue":"11","key":"10.1016\/j.trim.2024.102165_bb0155","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.trim.2024.102165_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med. J. Aust."},{"issue":"8","key":"10.1016\/j.trim.2024.102165_bb0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.trim.2024.102165_bb0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J. Intern. Med."},{"issue":"11","key":"10.1016\/j.trim.2024.102165_bb0175","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1080\/10428194.2018.1452221","article-title":"Multiple myeloma - a cure within reach","volume":"59","author":"Gertz","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.trim.2024.102165_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","article-title":"Resistance to the proteasome inhibitors: lessons from multiple myeloma and mantle cell lymphoma","volume":"1233","author":"Gonzalez-Santamarta","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"7","key":"10.1016\/j.trim.2024.102165_bb0185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.trim.2024.102165_bb0190","first-page":"608","article-title":"Drug-resistant mechanism of multiple myeloma and its therapy combined with HDACi -review","volume":"25","author":"Gu","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-020-01180-y","article-title":"Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance","volume":"19","author":"Cui","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0200","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/CAD.0000000000001166","article-title":"Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via modulating miR-223-3p\/BRD4 axis","volume":"33","author":"Liu","year":"2021","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0205","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-019-6088-0","article-title":"Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.trim.2024.102165_bb0210","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.trim.2024.102165_bb0215","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4155\/fmc-2021-0071","article-title":"GLUT1 biological function and inhibition: research advances","volume":"13","author":"Cao","year":"2021","journal-title":"Future Med. Chem."},{"issue":"9","key":"10.1016\/j.trim.2024.102165_bb0220","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-20-2870","article-title":"GLUT1 expression in tumor-associated neutrophils promotes lung Cancer growth and resistance to radiotherapy","volume":"81","author":"Ancey","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13058-016-0795-0","article-title":"The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis","volume":"18","author":"Wellberg","year":"2016","journal-title":"Breast Cancer Res.: BCR"},{"key":"10.1016\/j.trim.2024.102165_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2021.338593","article-title":"A GLUT1 inhibitor-based fluorogenic probe for Warburg effect-targeted drug screening and diagnostic imaging of hyperglycolytic cancers","volume":"1167","author":"Zhang","year":"2021","journal-title":"Anal. Chim. Acta"},{"issue":"2","key":"10.1016\/j.trim.2024.102165_bb0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2334\/josnusd.57.115","article-title":"GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma","volume":"57","author":"Angadi","year":"2015","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.trim.2024.102165_bb0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2022.06.020","article-title":"SUOX and GLUT1 are biomarkers for the prognosis in large duct type intrahepatic cholangiocarcinoma","volume":"128","author":"Kinjo","year":"2022","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.trim.2024.102165_bb0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-019-0305-9","article-title":"Glucose transporter 1 critically controls microglial activation through facilitating glycolysis","volume":"14","author":"Wang","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"11","key":"10.1016\/j.trim.2024.102165_bb0250","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1074\/jbc.M113.522037","article-title":"Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype","volume":"289","author":"Freemerman","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.trim.2024.102165_bb0255","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.40785","article-title":"Promotion of calcium\/calmodulin-dependent protein kinase 4 by GLUT1-dependent glycolysis in systemic lupus erythematosus","volume":"71","author":"Koga","year":"2019","journal-title":"Arthritis & Rheumatol. (Hoboken, NJ)"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T11:33:37Z","timestamp":1739100817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":51,"alternative-id":["S0966327424001813"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102165","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel insights into the circ_0003489\/let-7b-5p\/GLUT1 axis and its possible role in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102165"}}